Inventor
TOBIAS GINMAN
Inventor
SE
Overview
Patents· 8 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
A61Pprimary
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations29%
C07DHeterocyclic compounds29%
A61KPreparations for medical, dental or toiletry purposes25%
C07FAcyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium18%
PatentTitleYear
11,963,9636-heterocyclyl-4-morpholin-4-ylpyridine-2-one compounds useful for the treatment of cancer and diabetes202411,919,902Aryl-bipyridine amine derivatives as phosphatidylinositol phosphate kinase inhibitors202411,780,858Pyridinamine-pyridone and pyrimidinamine-pyridone compounds202311,633,4036-aryl-4-morpholin-1-ylpyridone compounds useful for the treatment of cancer and diabetes202311,584,763Chromenopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors202311,219,618Pyridylpyridone compounds202211,208,423Pyridinamine-pyridone and pyrimidinamine- pyridone compounds202111,179,3996-heterocyclyl-4-morpholin-4-ylpyridine-2-one compounds useful for the treatment of cancer and diabetes2021Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
2021–2024Patents assigned to SPRINT BIOSCIENCE AB (6)· patent assignee history
2021–2024Based in SE· patent location history
2023–2024Patents assigned to HIBERCELL INC (2)· patent assignee history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| SPRINT BIOSCIENCE AB | 6 | 2021–2024 |
| HIBERCELL INC | 2 | 2023–2024 |
Locations
| Location | Patents | Span |
|---|---|---|
| SE | 8 | 2021–2024 |